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ABSTRACT Peroxisome proliferator-activated receptors
(PPARs) are ligand-dependent transcription factors, and it is
assumed that the biological effects of these receptors depend
on interactions with recently identified coactivators, including
steroid receptor coactivator-1 (SRC-1). We assessed the in vivo
function of SRC-1 on the PPARa-regulated gene expression in
liver by generating mice in which the SRC-1 gene was inacti-
vated by gene targeting. The homozygous (SRC-12/2) mice
were viable and fertile and exhibited no detectable gross
phenotypic defects. When challenged with a PPARa ligand,
such as ciprofibrate or Wy-14,643, the SRC-12/2 mice dis-
played typical pleiotropic responses, including hepatomegaly,
peroxisome proliferation in hepatocytes, and increased mRNA
and protein levels of genes that are regulated by PPARa. These
alterations were indistinguishable from those exhibited by
SRC-11/1 wild-type mice fed either ciprofibrate- or Wy-
14,643-containing diets. These results indicate that SRC-1 is
not essential for PPARa-mediated transcriptional activation
in vivo and suggest redundancy in nuclear receptor coactivators.
Peroxisomes in hepatocytes can be induced to proliferate in
response to structurally diverse nonmutagenic chemicals des-
ignated as peroxisome proliferators (1, 2). These agents form
a broad group of compounds of industrial, pharmaceutical,
and agricultural value and include certain phthalate ester
plasticizers, leukotriene D4 antagonists, and hypolipidemic
drugs, such as clofibrate, ciprofibrate and Wy-14,643, among
others (2). The induction of peroxisome proliferation is me-
diated by peroxisome proliferator-activated receptor a
(PPARa), a member of the family of ligand-dependent nuclear
transcription factors that regulate the expression of genes
associated with lipid metabolism and adipocyte differentiation
(3–6). The PPAR subfamily has three isotypes (a, b or d, and
g), which exhibit distinct patterns of tissue distribution and
differ considerably in their ligand-binding domains and ligand
specificities, suggesting that they possibly perform different
functions in different cell types (5–8). Like other members of
the nuclear receptor superfamily, PPARs possess a central
DNA-binding domain that recognizes PPAR response ele-
ments (PPRE) in the promoter regions of target genes (2, 3,
9). PPARs form a heterodimer with the 9-cis-retinoic acid
receptor (RXR), to bind PPRE in DNA and transcriptionally
activate target genes (9).
Induction of peroxisome proliferation and the peroxisomal
fatty acid b-oxidation system in rats and mice by sustained
activation of PPARa either by exogenous or endogenous
ligands leads to the development of liver tumors (10, 11).
Recently, activation of PPARg by its ligands, troglitazone and
rosiglitazone, has been shown to induce a modest increase in
the incidence of spontaneously-occurring colon tumors in
Min1/2 mice lacking one copy of the APC tumor suppressor
gene (12, 13). Because these observations raise a potential
concern of risk to humans, it becomes essential to explore the
molecular mechanisms underlying tissue and species responses
to PPAR ligands. Transcriptional stimulation of gene expres-
sion by nuclear receptors by ligands involves the participation
of basal transcription factors, including TATA-binding protein
and TFIIB, and nuclear receptor coactivator proteins to form
a stable preinitiation macromolecular complex (14, 15). The
coactivators identified during the past 3 years include: steroid
receptor coactivator-1 (SRC-1) (16), SRC-2 [TIF-2yGRIP-1
(17, 18)], SRC-3 [ACTR (19)], AIB1 (20), pyCIP (21), and
RAC3 (22), CREB-binding protein (CBP)yp300 (23, 24),
PBPyTRAP220 (25, 26), PGC-1 (27), and ARA70 (28). We
cloned and identified mouse SRC-1 (29), a homologue of
human SRC-1 (16), and PBP (25) as coactivators of PPAR. To
study the physiological role of SRC-1 in PPAR-mediated
induction of pleiotropic responses, we inactivated the SRC-1
gene in mice by homologous recombination. We report that
homozygous SRC-1 mutants are viable and fertile and respond
to prototypical PPARa ligands in a manner similar to that of
SRC-11/1 wild-type mice, suggesting possible physiological
redundancy in vivo of coactivators in PPARa-mediated tran-
scriptional activation.
MATERIALS AND METHODS
Gene Targeting. P1 Genomic clone (#11189) containing the
SRC-1 gene was obtained by screening a mouse 129ySv P1
bacteriophage library (Genome Systems, St. Louis) by using
PCR with primers 59-TGACAGTAATTCTGGAATGT-
CAAT-39 and 59-GGGATTGCTGCTCTGGGAAC-39. P1
clone DNA was subjected to restriction analysis, and a 16-kb
PstI fragment was isolated for use in the construction of
targeting vector (Fig. 1A). This fragment covered two exons:
exon A, containing residues 317Met-366Arg and exon B, con-
taining residues 367Glu-873Arg (29). The targeting construct
was assembled in the pPNT targeting vector by using a 4.5-kb
NcoIyHindIII fragment and a 4-kb PstIyHindIII fragment of
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homologous mouse SRC-1 genomic sequences 59 and 39,
respectively, of the phosphoglycerate kinase promotery
neomycin-resistance complementary DNA (phosphoglycerate
kinase-neomycin) (Fig. 1 A). The targeting vector also con-
tained the herpes simplex thymidine kinase (hsv-tk) gene,
which allowed the use of a positive–negative selection scheme.
The final construct, designated pPNT-SRC-1, is illustrated in
Fig. 1A.
Generation of SRC-1 Mutant Mice. NotI-linearized target-
ing vector (30 mg) was electroporated into BK4 embryonic
stem (ES) cells that were selected in 200 mgyml G418 and 2 mM
ganciclovir (30, 31). One hundred G418-ganciclovir-resistant
ES colonies were picked up and subjected to Southern analysis;
seven were identified as having one normal and one targeted
disrupted allele. Two positive ES clones were injected into
3.5-day-old C57yBL6J blastocysts and transferred into pseu-
dopregnant CBAF1 foster female recipients. The resulting
chimeras were mated with C57yBL6J mice and germline
transmission was ascertained by coat color and confirmed by
Southern analysis with probes 1 and 2. F1 heterozygous siblings
for the disrupted SRC-1 gene were then mated to obtain
homozygous SRC-1 null mice.
Genotype of SRC-1 Mutant Mice. The offspring from sub-
sequent breeding were genotyped by PCR amplification and
confirmed by Southern analysis as needed. Two primers,
primers P1 (59-CCACCATCCAACAACAACATGG-39) and
P2 (59-AGCACTGTTGTCGCTGTTGTC-39), derived from
exon B of SRC-1 shown in Fig. 1 A, were designed to a detect
wild-type allele and two primers, primers P3 (59-TGAATG-
AACTGCAGGACGAGG-39) and P4 (59-CCACAGTCGAT-
GAATCCAGAA-39) from the neomycin cassette were used to
detect the SRC-1 targeted allele.
Reverse Transcription–PCR (RT–PCR). To confirm the
absence of SRC-1 mRNA in SRC-12/2 mice, RT-PCR was
performed by using primers 59-TTTCAAGAAGTGATGAC-
TCGTGG-39 in exon A either with 59-GGGATTGCTGCTC-
TGGGAAC-39or with 59-CCAGGATTGACTGAGGGATT-
-39, designed from the deleted region and the region 59- of the
deleted region in exon B, with resulting products of 465 bp and
240 bp, respectively. Another pair of primers, 59-TGACAG-
TAATTCTGGATG-39 in exon B undeleted region and 59-A-
ACTGGTTATCGATCGCTT-39 from the exon following
exon B amplified the 1,533-bp fragment. Total RNA extracted
from liver, kidney, and colon from wild-type and SRC-12/2
mice was used in the one-step RT-PCR system (GIBCOyBRL)
for cDNA synthesis.
Treatment with Peroxisome Proliferators. Wild-type and
SRC-12/2 mice were fed powdered diet with or without
PPARa ligands, ciprofibrate (0.0125% wtywt) or Wy-14,643
(0.1% wtywt) for 4 to 14 days. For cell proliferation analysis,
mice were given bromodeoxyuridine (0.5 mgyml) in drinking
water for 4 days and their livers processed for immunohisto-
chemistry. To assess the dose response, groups of three
wild-type and SRC-12/2 mice were given a single intragastric
dose of ciprofibrate (150, 75, 37.5, 18.75, or 0 mgykg body
weight) and killed 24 h later.
Western Blot Analysis. Liver extracts were subjected to 10%
SDSyPAGE and transferred to nitrocellulose membranes.
Immunoblotting was performed by using rabbit polyclonal
antibodies against rat peroxisomal acyl-CoA oxidase (AOX),
peroxisomal L- and D-type bifunctional protein (enoyl-CoA
hydratasey3-hydroxyacyl-CoA dehydrogenase) (L-PBE, and
D-PBE), peroxisomal 3-ketoacyl-CoA thiolase (THL), cata-
lase (CAT), urate oxidase, sterol carrier protein x, short-chain
acyl-CoA dehydrogenase (SCAD), medium-chain acyl-CoA
dehydrogenase (MCAD), and very long-chain acyl-CoA de-
hydrogenase (VLCAD), as described (32). Antibodies against
SRC-1 were from a commercial source, or were a generous gift
of Bert O’Malley, Baylor College of Medicine, Waco, TX. The
membranes were incubated with the primary antibody fol-
lowed by alkaline phosphatase-conjugated goat anti-rabbit
IgG (Sigma).
Northern Hybridization. For northern analysis, total RNA
(20 mg) extracted from wild-type and SRC-12/2 mice by Trizol
reagent (GIBCOyBRL) was glyoxylated, separated on 0.8%
agarose gel, and transferred to nylon membrane. cDNA probes
used for Northern blotting included AOX, L-PBE, THL,
cytochrome P450 (CYP)4A1, CYP4A3, b-actin, and ribosomal
FIG. 1. Generation of SRC-1-deficient mice. (A) Schematic rep-
resentation of the mouse SRC-1 gene, targeting vector, and the
structure of the locus after gene targeting. Two exons, A and B, in the
SRC-1 gene are shown as closed boxes. Restriction sites are indicated.
Location of hybridization probes used for Southern blot analysis and
of PCR primers used for genotyping are shown. (B) Southern blot
analysis of genomic DNA. Genomic DNA (5 mg) isolated from the tail
tips of 2- to 3-week-old pups was digested with PstI, transferred to
membranes, and hybridized with the 59 probe (probe 1 shown in A).
Lanes: SRC-11/1 wild type, SRC-11/2 heterozygous, SRC-12/2 ho-
mozygous mice. The 16-kb band corresponds to the wild-type allele
and the 7.5-kb band corresponds to the rearranged allele. (C) RT-PCR
analysis of liver (L), kidney (K), and colon (C) of SRC-11/1 and
SRC-12/2 mice by using primers from different regions (see Methods).
The expected sizes of the PCR products (465, 240, and 1,533 bp) are
indicated. Lanes 1/1, wild type and 2y2, homozygote. The SRC-1
transcript is not detected in tissues of SRC-12/2 mice. (D) Northern
blot analysis using Poly(A)1 RNA (5 mgylane) isolated from liver
probed with SRC-1 or b-actin cDNA reveals absence of SRC-1
transcript in SRC-1 null mouse liver. Note the presence of b-actin
mRNA both. (E) Western blot analysis for SRC-1 expression in
wild-type and SRC-1 mutant mice. Liver extracts (100 mg) were
immunoblotted by using a monoclonal antibody; no immunodetectable
SRC-1 protein is seen in SRC-12/2 mouse.
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RNA (28 S). Poly(A)1 RNA extracted from liver was used for
SRC-1 analysis. Changes in mRNA levels were estimated by
densitometric scanning of autoradiograms.
Histology and Electron Microscopy. For light microscopy,
tissues were fixed in 10% neutral buffered formalin and
embedded in paraffin by using standard procedures. Sections
(4-mM thick) were cut and stained with hematoxylin and eosin.
For cytochemical localization of catalase, tissues were fixed in
1.5% glutaraldeyde in 0.1 M sodium cacodylate buffer (pH 7.4)
for 4 h at 4°C and processed as described (10, 30). Semithin
sections, without counterstain, were examined by light micros-
copy. Ultrathin sections for electron microscopy were con-
trasted with uranyl acetate and lead citrate.
RESULTS
Disruption of PPAR-Binding Site of SRC-1 Coactivator.
The mouse SRC-1 cDNA that we and others have cloned (23,
24, 29) is the homologue of human SRC-1(16). We have shown
that it functions as a coactivator for PPARs (29). We identified
two PPAR binding regions in SRC-1 (29); one region located
between residues 620–789 displayed stronger interaction with
PPAR than the second one, located at the carboxy terminus
(residues 1231–1447). The region between amino acids 620 and
789 contains three highly conserved LXXLL motifs, demon-
strated recently to be sufficient and necessary for the binding
of several coactivators to nuclear receptors (21, 33). The
carboxy-terminal region of mouse SRC-1 contains one
LXXLL motif (29). Accordingly, we decided to disrupt the
region containing the first PPAR interacting domain with
three LXXLL motifs. We isolated a 16-kb SRC-1 genomic
fragment that contained two exons, one of which, designated
exon B, includes amino acid residues 620–789. The gene
targeting vector, pPNT-SRC-1, was designed to delete this
region (exon B shown in Fig. 1 A) and to replace it with
phosphoglycerate kinase-neomycin gene (Fig. 1 A). A correct
gene targeting event would result in a protein, if any, that lacks
the three critical LXXLL motifs functional in this region.
Generation of Mice with a Modified SRC-1 Gene. pPNT-
SRC-1 was introduced into BK4 ES cells by electroporation. Of
the 100 G418-ganciclovir-resistant colonies analyzed by South-
ern blotting, seven displayed one normal and one disrupted
SRC-1 allele. ES cells from two clones were injected into
C57BLy6J blastocysts to generate chimeras. Chimeras from
both lines were able to transmit the mutant allele to the
offspring after outbreeding with C57yB6J.
Mice heterozygous for the disrupted SRC-1 gene were
phenotypically normal. These heterozygous F1 mice were
intercrossed to obtain homozygous mutant offspring (Fig. 1B).
The F1 progeny exhibited the predicted Mendelian frequency
of 25% homozygous mutant offspring and the SRC-12/2 mice
exhibited no apparent morphological abnormalities. Both male
and female homozygous mice grew normally, survived longer
than 10 months, and were fertile. No significant differences in
body weight and liver weight were found between age-matched
SRC-11/1 and SRC-12/2 mice. The absence of expression of
the SRC-1 transcript in liver, kidney, and colon of SRC-1 null
mice was confirmed by RT-PCR (Fig. 1C). Northern blot
analysis using Poly(A)1 RNA isolated from the liver also
showed the absence of SRC-1 mRNA in SRC-12/2 mouse (Fig.
1D).Western blotting revealed no immunodetectable SRC-1
protein in the liver of SRC-1 mutant mice (Fig. 1E).
Induction of Peroxisome Proliferation in SRC-1 Mutant
Mice. Wild-type mice treated with a peroxisome proliferator,
such as ciprofibrate or Wy-14,643, exhibit profound increases
in the number and volume density of peroxisomes in their liver
cells (1). To assess the impact of SRC-1 gene disruption, if any,
on PPARa-regulated pleiotropic responses, including liver cell
proliferation and hepatic peroxisome proliferation, we studied
the inductive response after dietary feeding of ciprofibrate or
Wy-14,643. No significant differences in hepatomegaly and
bromodeoxyuridine labeling were noted between wild-type
and SRC-1 null mice treated with a peroxisome proliferator for
4 days (Fig. 2). Light microscopic evaluation of sections of liver
that were processed to visualize peroxisomal catalase revealed
marked increases in the number and size of peroxisomes in
hepatic parenchymal cells of SRC-11/1 wild-type and SRC-1
null mice treated with a peroxisome proliferator (Fig. 3). The
magnitude of peroxisome proliferation, as assessed by light
(Fig. 3) and electron microscopy (not illustrated), was similar
in both groups. Thus, SRC-1 null mice exhibited no resistance
to either ciprofibrate or Wy-14,643 at the dose level adminis-
tered, as evidenced by hepatomegaly and peroxisome prolif-
eration.
FIG. 2. Cell proliferation in the liver. SRC-11/1 wild type and SRC-12/2 mice were fed Wy-14,643 (0.1% wtywt) in the diet for 4 days and were
also given bromodeoxyuridine in drinking water (0.5 mgyml). Liver sections were processed for immunohistochemical demonstration of
bromodeoxyuridine uptake. Nuclear labeling (arrows) is seen in hepatocytes. (A) SRC-11/1 and (B) SRC-12/2 mice fed Wy-14,643. (C) SRC2/2
mice fed a control diet.
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PPARa-Regulated Fatty Acid-Metabolizing Enzymes in the
Liver of SRC-1 Mutant Mice. To assess the influence of SRC-1
on PPARa function, we evaluated fatty acid-metabolizing
enzymes in SRC-1 null mutants by immunoblotting. We ex-
amined constitutive and inducible levels of fatty acid-
metabolizing enzymes in liver. Constitutive levels of hepatic
peroxisomal fatty acid b-oxidation enzyme expression of
AOX, L-PBE, and THL were not significantly different be-
tween wild-type and SRC-1 null mice (Fig. 4). These three
enzymes were induced .25-fold in both wild-type and SRC-1
null mice fed a diet containing Wy-14,643, a PPARa ligand, for
two weeks (Fig. 4). The constitutive levels of expression in liver
of peroxisomal D-PBE, sterol carrier protein x, CAT, and urate
oxidase in wild-type and SRC-1-deficient mice were essentially
similar and only a '3-fold increase in the levels of these
proteins occurred after Wy-14,643 administration in both
SRC-11/1 and SRC-12/2 mice (Fig. 4). We also determined the
constitutive expression of hepatic mitochondrial enzymes
SCAD, MCAD, and VLCAD that are involved in lipid me-
tabolism and found no significant differences between wild-
type and SRC-1 null mice. There was a significant increase in
the expression of MCAD in both SRC-11/1 and SRC-12/2
mouse liver following Wy-14,643 treatment. We also examined
the effect of administration of ciprofibrate on fatty acid-
metabolizing enzymes and found no significant differences in
responsiveness between SRC-11/1 and SRC-12/2 mice (data
not shown).
To extend these observations further, we measured total
hepatic b-oxidation using palmitic acid (C-16). The basal level
of total fatty acid b-oxidation in wild-type and SRC-1 null mice
was similar and, as expected, administration of Wy-14,643, a
PPARa ligand, caused a significant increase in fatty acid
metabolism in wild-type and SRC-12/2 mice (Fig. 5A). The
constitutive level of peroxisomal b-oxidation in the liver of
SRC-1 null mice was similar to that found in the wild-type mice
(Fig. 5B). Both SRC-11/1 and SRC-12/2 mice exhibited an
identical increase in b-oxidation activity after Wy-14,643 treat-
ment (Fig. 5B).
Expression of mRNAs. To further affirm PPARa activation,
the structural findings are extended by analysis of the hepatic
mRNA levels by Northern blotting. Constitutive levels of
AOX, L-PBE, THL, and CYP4A1 mRNA were similar in the
livers of both wild-type and SRC-1 null mice (Fig. 6). The
FIG. 3. Peroxisome proliferation in liver parenchymal cells of
wild-type and SRC-1 mutant mice treated with ciprofibrate. Light
microscopic appearance of liver as revealed in semithin (0.5 mM thick)
sections of tissue that was processed for the cytochemical localization
of peroxisomal catalase by using the alkaline 39,39-diaminobenzidine
substrate. A and C represent SRC-11/1 wild-type and SRC-12/2 mice,
respectively, maintained on control chow. Peroxisomes appear as
brown dots (arrows) randomly distributed in the cytoplasm. B and D
represent SRC-11/1 and SRC-12/2 mice, respectively, which were fed
a diet containing ciprofibrate for 2 weeks. Both wild-type and SRC-1
mutant mice display a robust degree of peroxisome proliferation, as
evidenced by numerous brown granules (arrows).
FIG. 4. Western blot analysis of selected fatty acid-metabolizing
and other enzymes in liver. Liver homogenates from SRC-11/1 and
SRC-12/2 mice fed either control or Wy-14,643-containing diet were
subjected to SDSyPAGE and immunoblotting (three mice for each
group). AOX (lane 1; 5 mg), L-PBE (lane 2; 20 mg), THL (lane 3; 5
mg), D-PBE (lane 4; 20 mg), sterol carrier protein x (lane 5; 10 mg),
SCAD (lane 6; 20 mg), MCAD (lane 7; 20 mg), VLCAD (lane 8; 2 mg),
urate oxidase (lane 9; 2 mg) and CAT (lane 10; 2 mg).
FIG. 5. Hepatic fatty acid b-oxidation in SRC-11/1 wild type and
SRC-12/2 mice. Fatty acid b-oxidation of palmitic acid was measured
and the values expressed as nmolymin per gm liver. (A) Mitochondrial
plus peroxisomal and (B) peroxisomal. Solid bars and open bars are
from wild-type and SRC-1 null mice, respectively, fed a control or
Wy-14,643-containing (0.1% wtywt) diet for 7 days. A significant
difference was not found between wild-type and SRC-1 null mutants
fed a peroxisome proliferator, but the induction is significant in both
when compared with their respective untreated controls.
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AOX, L-PBE, THL, and CYP4A1 hepatic mRNA levels
increased markedly and identically in both wild-type and
SRC-1-deficient mice fed a peroxisome proliferator (Fig. 6).
Dose Response to Ciprofibrate. To determine whether
SRC-1 null mice are possibly less sensitive to a PPARa ligand
at lower dose levels than wild-type mice, we administered a
single dose of ciprofibrate (ranging from 0 to 150 mgykg body
weight) by gavage and analyzed changes in hepatic CYP4A1
and L-PBE mRNA levels 24 hr after dosing by Northern
blotting. Both wild-type and SRC-l null mice responded in a
similar manner to different dose levels of ciprofibrate admin-
istered, indicating that response to PPARa ligand is not
subdued in SRC-1-deficient mice (data not shown).
DISCUSSION
Ligand-inducible transcriptional activation by nuclear recep-
tors is now known to involve the participation of proteins
termed coactivators that link the receptors with the basal
transcriptional apparatus (14–16, 23, 34). The interaction of
coactivators with nuclear receptors is ligand dependent and
occurs through the carboxy-terminal helical region of the
receptor, referred to as activation function-2 domain (15, 35).
This region serves as the ligand-binding pocket and undergoes
a conformational change that facilitates protein–protein in-
teractions, enabling the recruitment of coactivator proteins for
efficient gene transcription (23). Some of these coactivators,
for example CBPyp300 (36), SRC-1 (37), and ACTR (19),
possess intrinsic histone acetyltransferase activities capable of
modifying the chromatin organization of the target gene
promoter regions.
Of the various nuclear receptor coactivators identified to
date, SRC-1 (29), CBPyp300 (38, 39), PBP (25), and PGC-1
(27) have been shown to mediate transcriptional activation of
PPARs. Mammalian PPARs are members of the nuclear
receptor superfamily of ligand-activated transcription factors
that bind to PPRE as heterodimers with RXR and regulate
expression of genes involved in lipid homeostasis and differ-
entiation (3, 7, 10, 40). PPRE is a degenerate direct repeat of
the canonical AGGTCA sequence separated by a single nu-
cleotide (so-called DR1) (2, 9, 35, 41) that is located in the
promoter region of PPAR-regulated genes. Several structur-
ally diverse synthetic peroxisome proliferators have long been
known to induce predictable pleiotropic responses by a recep-
tor-mediated mechanism (1, 2), and the recent identification of
additional synthetic and natural agonists of PPARa and
PPARg raises issues regarding the cell- and species-specific
nature of their biological effects in extrapolating potential risk
to humans from long-term exposure (11–13, 42). Responses to
PPAR agonists may well be influenced by pharmacokinetics,
relative abundance of PPAR isotypes in specific cell types and
their affinity for agonists, the nature of PPRE in the upstream
regions of target genes, the extent of competition or crosstalk
among nuclear transcription factors for PPAR heterodimer-
ization partner RXR, and the modulating role of coactivators
and corepressors (29, 30, 43). Given the plethora of pleiotropic
responses elicited by natural and synthetic PPAR agonists and
their extensive clinical use and importance, it is of great
interest and relevance to dissect the molecular basis for each
of the above variables. Our laboratory has characterized mouse
SRC-1 (29) and PBP (25) genes and identified them as PPAR
coactivators. Studies from other laboratories have shown that
CBPyp300 (38, 39) and PGC-1 (27) also enhance transactiva-
tion by PPARs. As a first step in exploring the physiological
role in vivo of various coactivators in nuclear receptor activity
in general and in PPAR-regulated gene expression in partic-
ular, we have used homologous recombination to disrupt the
mouse SRC-1 gene and have investigated the response of
SRC-1 null mice to PPARa agonists.
Disruption of the SRC-1 gene by deletion of an exon that
contains three conserved helical motifs of the consensus
sequence LXXLL necessary for interaction with nuclear re-
ceptors led to the generation of SRC-1 null mutants. These
mutant animals grow and reproduce normally, suggesting that
their somatic and sexual development is essentially normal.
The major finding of this study is that mice lacking the SRC-1
gene display no discernible differences when compared with
wild-type littermates. These observations suggest that the
absence of this coactivator does not adversely affect the
developmental and physiological profiles, implying possible
redundancy of coactivators in nuclear receptor function. In this
study, mice lacking SRC-1 did not exhibit any appreciable
differences, as compared with wild-type animals, in liver
weight, hepatocellular proliferation, increases in peroxisome
population in liver cells, or changes in the levels of expression
of enzymes involved in fatty acid metabolism when challenged
with PPARa ligands. The absence of significant differences in
response between wild-type and SRC-1 mutant mice after
exposure to peroxisome proliferators suggests that SRC-1
coactivator does not play an essential role in PPARa-regulated
transcriptional activation in vivo. Alternatively, the SRC-1 is so
pivotal that the loss of its function is compensated for by other,
possibly redundant, coactivators, such as CBP, PBP, PGC-1, or
other yet-to-be-discovered proteins.
In this study, we examined the immediate or early responses
to PPARa agonists in the liver of SRC-1 mutant mice and,
judging from the robust peroxisome proliferative response,
one can speculate that these animals would most likely develop
liver tumors after chronic exposure to peroxisome prolifera-
tors. Additional studies are nonetheless needed to test the
response of SRC-1 null mice to PPARg ligands and other
stresses before one can conclude with certainty that SRC-1
does not play an appreciable role in PPAR-regulated tran-
scriptional activation in vivo. Because SRC-1 and other coac-
tivators identified to date interact in vitro with other nuclear
receptors, the SRC-1 null mice would serve as valuable animal
models to test the functional implications of this coactivator in
vivo on the functioning of other nuclear receptors. In a recent
report, SRC-1 gene-disrupted mice were found to exhibit
somewhat subdued responses to sex hormonal stimuli after
orchiectomy or ovarietcomy, although the intact animals were
fertile and appeared hormonally indistinguishable from SRC-
11/1 mice (44). The partial hormone resistance of target tissues
FIG. 6. Northern blot analysis of total RNA extracted from liver of
SRC-11/1 wild type and SRC-12/2 mice. RNA (20 mg) from mice fed
a control or ciprofibrate- (0.0125% wtywt) containing diet (Cip) for 2
weeks was probed with different random-primed 32P-labeled cDNA
probes as shown. AOX, L-PBE, THL, CYP4A1, and CYP4A3 (not
shown) are genes that contain PPRE in their promoters and are
regulated by PPARa. 28S rRNA is used as loading indicator.
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in castrated SRC-1 null mice suggests that coactivators such as
SRC-1 may function more efficiently in certain cell types and
may possibly play a more specific role in transcriptional activity
in vivo of a subset of nuclear receptors (40, 43, 45). Additional
data are needed to explore the role of various coactivators by
generating mutant mice with defects in one or more coacti-
vator functions.
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